News and Reports
-
SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors
22 July 2020Download -
Bioatla Raises $72.5 Million in Series D Financing
15 July 2020Download -
C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-concept and to Advance Proprietary Platform
16 June 2020Download -
Viela Bio Announces U.S. FDA Approval of UPLIZNA? (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
11 June 2020Download -
Novo Nordisk to acquire Corvidia Therapeutics and expand presence in cardiovascular disease
11 June 2020Download -
Everest Medicines Completes US$310 Million Series C Financing
4 June 2020Download -
Swixx and Amryt sign CEE Distriubtion Deal on Myalepta June 3, 2020
3 June 2020Download -
Y-mAbs Announces U.S. FDA Acceptance of Biologics License Application for Danyelza? (Naxitamab) for the Treatment of Neuroblastoma for Priority Review
2 June 2020Download -
Galecto Appoints New Chair and Strengthens Board of Directors
19 May 2020Download -
iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
27 April 2020Download -
Y-mAbs enters into Worldwide Exclusive License Agreement for SADA Technology – a Novel Radioimmunotherapy Platform
15 April 2020Download -
iTeos Therapeutics Closes $125 Million Series B2 Financing
1 April 2020Download -
SWIXX Signs Distribution Deal with UPSA for Russia
30 March 2020Download -
Karius Secures $165 Million Series B Funding Led by Softbank Vision Fund 2
24 February 2020Download -
Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock
21 February 2020Download -
SWIXX AND NORGINE SIGN DEAL ON PLENVU FOR CEE
13 February 2020Download -
ALX Oncology Announces Closing of $105 Million Series C Financing
12 February 2020Download -
Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares
4 February 2020Download -
Harmony Biosciences Secures $200 Million Debt Facility
27 January 2020Download -
Neurelis announces FDA approval for seizure rescue treatment VALTOCO®
13 January 2020Download -
Arcutis Announces ARQ-154 Program for Seborrheic Dermatitis and Enrollment of First Patient in Phase 2 Proof of Concept Clinical Trial
5 December 2019Download -
Arcutis Biotherapeutics Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Phase 3 Program for ARQ-151 for Plaque Psoriasis
24 October 2019Download -
Arcutis Announces the Completion of $94.5 million Series C Financing
21 October 2019Download -
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
10 October 2019Download -
Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares
7 October 2019Download